Eli Lilly & Co is a general drug manufacturer company located in Indiana, United States, which is part of the Healthcare sector, and is traded under the ticker LLY on the NYSE exchange.
Eli Lilly & Co stock last closed at $732.58, up 0.08% from the previous day, and has decreased 22.08% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.08 percentage points. Eli Lilly & Co stock is currently +17.44% from its 52-week low of $623.78, and -24.45% from its 52-week high of $969.65.
At the moment, there are 946.46M shares of LLY outstanding. The market cap of LLY is $693.36B. In the past 24 hours, 2.55M LLY shares were traded.
You will need a brokerage account in order to access the NYSE market and buy LLY stock.
In our opinion, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your stock purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the right brokerage, you need to fill out some personal info so you can invest in LLY today.
Now that you've filled out your info on the best app for stock investing, you need to deposit funds:
Check out the video below for more details transferring money into your new investment account.
After you have identified the best place to buy Eli Lilly & Co stock, it's important to research their stock before you invest, so you can wrap your head around the risk and opportunity.
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis.
You can see all of the due diligence checks on LLY's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge LLY's true value.
Using relative valuations ratios:
You can do additional valuation analysis on LLY's stock here.
Out of 9 Equities analysts who give recommendations on LLY, the consensus analyst rating on LLY is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Chris Schott, a top 22% analyst from JP Morgan reiterates LLY with a strong buy rating and maintains their LLY price target from $1,100.00 to $1,100.00, on Aug 8, 2025.
JP Morgan's Chris Schott reiterated their Strong Buy rating on Eli Lilly & Co (NYSE: LLY). The analyst also maintained a $1,100 price target.
Eli Lilly & Co. reported its Q2 2025 earnings on 2025/08/07.
Schott said they believe some worries about the weight loss industry should be allayed following the quarter's earnings beat and management guidance raise.
The primary emphasis on the call was the Phase 3 obesity data for orforglipron, which showed a little lower weight loss than anticipated, the analyst added.
According to Schott, 1% to 2% less weight loss will not significantly alter the orforglipron usage scenario.
For Q2 2025, Eli Lilly & Co reported:
For FY 2025, management guided:
Chairman and CEO David A. Ricks commented: "Lilly delivered another quarter of strong performance, achieving 38% Y/Y revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines.
"Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health—including Mounjaro's demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and strong data for our oral incretin, orforglipron, in obesity.
“We also expanded manufacturing capacity to meet increasing demand and invested in key R&D initiatives to support our long-term growth."
Terence Flynn, a top 12% analyst from Morgan Stanley maintains LLY with a strong buy rating and raises their LLY price target from $1,133.00 to $1,135.00, on Jul 10, 2025.
Asad Haider, a bottom 45% analyst from Goldman Sachs upgrades LLY to a strong buy rating and lowers their LLY price target from $892.00 to $888.00, on Apr 8, 2025.
Mohit Bansal, a top 18% analyst from Wells Fargo maintains LLY with a strong buy rating and raises their LLY price target from $970.00 to $1,100.00, on Mar 5, 2025.
You can dive deeper into what analysts are forecasting on the Eli Lilly & Co stock forecast page.
Last year, LLY earnings were $13.80B. Over the past five year, LLY's earnings have grown by 19.92% per year. This was faster than the Drug Manufacturers - General industry average of 6.07%.
Last year, LLY revenue was $53.26B. During the past five year, LLY's revenue has gone up by 18.34% per year. This was faster than the Drug Manufacturers - General industry average of 9.87%.
Dig into LLY's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at LLY have sold more shares than they have bought.
Donald A. Zakrowski, SVP Finance CAO of LLY, was the latest LLY insider to sell. They sold $734,930.00 worth of LLY stock on Aug 28, 2025.
Research more about who owns LLY stock here.
Eli Lilly & Co pays a dividend of 0.59%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.03%. If you owned $1,000 of LLY stock, you would have been paid $5.87 in the past 12 months.
Eli Lilly & Co dividend payments have consistently grown over the past decade and have remained stable.
Dig into more data about Eli Lilly & Co dividend yield and history here.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
You have two main types of orders:
Press the Open Trade button and eToro will execute your order.
If you want additional help investing in stocks on eToro, watch the how to video below:
Now that you own some LLY shares, you'll want to keep up with your company.
Create a watchlist to see the latest developments about your LLY stock.
To reiterate, here are the 6 steps you need to take to buy Eli Lilly & Co stock right now:
If you are looking for a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Eli Lilly & Co, add LLY to your watchlist by clicking the button below.